Actavis Says US Appeals Court Upholds Patent Of Lo Loestrin Fe

(RTTNews) - Irish specialty pharmaceutical company Actavis plc (ACT) Thursday confirmed that the United States Court of Appeals for the Federal Circuit has upheld a lower court ruling on its birth control pill Lo Loestrin Fe. Earlier in January, US District court of New Jersey has found United States Patent No. 7,704,984 (the '984 Patent) to be valid and infringed by Lupin Pharmaceuticals, Inc. and Amneal Pharmaceuticals' Abbreviated New Drug Applications the pills.

As a result of the appeals court's ruling, Lupin and Amneal are prevented from launching their generic versions of Lo Loestrin Fe until after the '984 Patent expires on February 2, 2029.